PharmaCyte Biotech (PMCB) Share-based Compensation (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Share-based Compensation of $54579.0 for Q1 2026, down 25.09% year-over-year from $72859.0 in Q1 2025, and down 9.77% quarter-over-quarter from $60492.0 in Q4 2025.
PharmaCyte Biotech (PMCB) Share-based Compensation (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Share-based Compensation for 16 consecutive years, with $54579.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 25.09% year-over-year to $54579.0; the TTM figure through Apr 2026 stood at $133351.0 (down 67.84% YoY), while the FY2026 annual figure was $892500.0, up 278.09% from the prior year.
- Share-based Compensation retreated to $54579.0 in Q1 2026 per PMCB's latest filing, from $60492.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $913640.0 in Q3 2023 and bottomed at -$913640.0 in Q2 2024.
- Historically, Share-based Compensation has averaged $99907.9 across 5 years, with a median of $57535.5 in 2025.
- Annual changes were most pronounced in 2023 — Share-based Compensation sank 91.95% — and 2024, when it jumped 101053.37%.
- PharmaCyte Biotech's Share-based Compensation stood at $3917.0 in 2022, then soared by 23224.99% to $913640.0 in 2023, then sank by 86.96% to $119155.0 in 2024, then plunged by 49.23% to $60492.0 in 2025, then fell by 9.77% to $54579.0 in 2026.
- Business Quant data shows PMCB's Share-based Compensation at $54579.0 in Q1 2026, $60492.0 in Q4 2025, and $175562.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | PharmaCyte Biotech | 4.30 Mn | 4.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 54,579.00 |
| Jan 31, 2026 | 54,579.00 |
| Oct 31, 2025 | 60,492.00 |
| Oct 31, 2025 | 60,492.00 |
| Jul 31, 2025 | 175,562.00 |
| Jul 31, 2025 | 175,562.00 |
| Jan 31, 2025 | 72,859.00 |
| Jan 31, 2025 | 72,859.00 |
| Oct 31, 2024 | 119,155.00 |
| Oct 31, 2024 | 119,155.00 |
| Jul 31, 2024 | 222,677.00 |
| Jul 31, 2024 | 222,677.00 |
| Apr 30, 2024 | -913,640.00 |
| Apr 30, 2024 | -913,640.00 |
| Jan 31, 2024 | 674,693.00 |
| Jan 31, 2024 | 674,693.00 |
| Jul 31, 2023 | 913,640.00 |
| Jul 31, 2023 | 913,640.00 |
| Jan 31, 2023 | 667.00 |
| Jan 31, 2023 | 667.00 |